Alexion Pumps Up Its Rare Disease Portfolio With Enobia Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Alexion could pay as much as $1.08 billion for access to Enobia's mid-stage rare disease compound asfotase alpha.
You may also be interested in...
No One-Trick Pony: Alexion’s Evolution Into A Multi-Asset Drug Company
Alexion has been recognized mainly as the marketer of Soliris since 2007, but in just eight weeks the rare disease specialist added two new drugs to its commercial portfolio. Management also laid out an impressive early- to mid-stage pipeline during its first-ever investor day, suggesting the company is well positioned for long-term growth.
Alexion’s Bell Notes The Changing Role Of Innovation In Regulatory Decisions
CEO of the ultra-rare disease focused biotech spoke about the challenges of launching a drug for a relatively unknown disease and how innovation is playing an increasing role in R&D.
Breakthrough Math: Alexion Gains $400 Million on Asfotase Breakthrough Designation
There’s a lively debate underway as to what FDA’s new breakthrough designation means for a sponsor and for the likelihood of a product’s regulatory and commercial success. Alexion’s post-Memorial Day bump dramatizes the positive impact on Wall Street.